Novel Non-Cyclooxygenase Inhibitory Derivative of Sulindac Inhibits Breast Cancer Cell Growth In Vitro and Reduces Mammary Tumorigenesis in Rats

Novel Non-Cyclooxygenase Inhibitory Derivative of Sulindac Inhibits Breast Cancer Cell Growth In Vitro and Reduces Mammary Tumorigenesis in Rats

The nonsteroidal anti-inflammatory drug (NSAID) sulindac demonstrates attractive anticancer activity, but the toxicity resulting from cyclooxygenase (COX) inhibition and the suppression of physiologically important prostaglandins precludes its long-term, high dose use in the clinic for cancer preven...

Full description

Bibliographic Details
Main Authors: Heather N. Tinsley, Bini Mathew, Xi Chen, Yulia Y. Maxuitenko, Nan Li, Whitney M. Lowe, Jason D. Whitt, Wei Zhang, Bernard D. Gary, Adam B. Keeton, William E. Grizzle, Clinton J. Grubbs, Robert C. Reynolds, Gary A. Piazza
Format: Article
Language:English
Published: MDPI AG 2023-01-01
Series:Cancers
Subjects:
nonsteroidal anti-inflammatory drug (NSAID)
cyclooxygenase (COX)
cyclic guanosine monophosphate (cGMP)
phosphodiesterase (PDE)
breast cancer
sulindac
Online Access:https://www.mdpi.com/2072-6694/15/3/646

Internet

https://www.mdpi.com/2072-6694/15/3/646

Similar Items